Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma

Clinical Cancer Research

Volumn 8, Issue 12, 2002, Pages 3658-3668

  Bahlis, Nizar J ^a,b,e   McCafferty Grad, Jennifer ^a,c   Jordan McMurry, Ileana ^a   Neil, Jim ^d   Reis, Isildinha ^a   Kharfan Dabaja, Mohamed ^a,b,f   Eckman, James ^d   Goodman, Mark ^a,b   Fernandez, Hugo F ^a,b   Boise, Lawrence H ^a,c   Lee, Kelvin P ^a,b,c,g  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; GLUTATHIONE; THALIDOMIDE;

ADULT; AMINO ACID ANALYSIS; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEASIBILITY STUDY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; MALE; MEDICAL SOCIETY; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; ASCORBIC ACID; DRUG RESISTANCE, NEOPLASM; FEASIBILITY STUDIES; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; OXIDES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0036896388     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Anderson, K. C. Who benefits from high-dose therapy for multiple myeloma?. J. Clin. Oncol., 13: 1291-1296, 1995.
2. Kovacsovics, T. J., and Delaly, A. Intensive treatment strategies in multiple myeloma. Semin. Hematol., 34: 49-60, 1997.
3. Lokhorst, H. M., Sonneveld, P., and Verdonck, L. F. Intensive treatment for multiple myeloma: where do we stand?. Br. J. Haematol., 106: 18-27, 1999.
4. Dalton, W. S., Grogan, T. M., Meltzer, P. S., Scheper, R. J., Durie, B. G., Taylor, C. W., Miller, T. P., and Salmon, S. E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol., 7: 415-424, 1989.
5. Sonneveld, P., Durie, B. G., Lokhorst, H. M., Frutiger, Y., Schoester, M. and Vela, E. E. Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Br. J. Haematol., 83: 63-67, 1993.
6. Anderson, K. C., Kyle, R. A., Berenson, J. R., and Dalton, W. S. Recent advances in the biology and treatment of multiple myeloma. Hematology, 63-88, 1998.
7. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., and Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 93: 1658-1667, 1999.
8. Kickhoefer, V. A., Rajavel, K. S., Scheffer, G. L., Dalton, W. S., Scheper, R. J., and Rome, L. H. Vaults are up-regulated in multidrugresistant cancer cell lines. J. Biol. Chem., 273: 8971-8974, 1998.
9. Zawydiwski, R., Harmon, J. M., and Thompson, E. B. Glucocorticoid-resistant human acute lymphoblastic leukemic cell line with functional receptor. Cancer Res., 43: 3865-3873, 1983.
10. Grad, J. M., Bahlis, N. J., Reis, I., Oshiro, M. M., Dalton, W. S., and Boise, L. H. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 98: 805-813, 2001.
11. Buzaid, A. C., and Durie, B. G. Management of refractory myeloma: a review. J. Clin. Oncol., 6: 889-905, 1988.
12. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissic, E., Wilson, C., Dhodapkar, M., Zeddis, J., and Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 341: 1565-1571, 1999.
13. Zhang, P., Wang, S., Hu, L., Shi, F., Qiu, F., Hong, L., Han, X., Yang, H., Song, Y., Liu, Y., Zhou, J., Li, X., Xiao, Y., and Jin, Z. Treatment of acute promyelocytic leukemia with intravenous arsenic trioxide. Chinese J. Hemat., 17: 58-60, 1996.
14. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89: 3354-3360, 1997.
15. Shen, Z. X., Chen, G. Q., Li, X. S., Ni, J. H., Tang, W., Fang, Z. W., Chen, S. J., Wang, Z. Y., and Chen, Z. Use of arsenic trioxide in the treatment of APL. II. Remission induction in relapsed patients and pharmacokinetics. Blood, 88: 292a, 1996.
16. Soignet, S. L., Maslak, P., Wang, Z. G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., Pandolfi, P. P., and Warrell, R. P. J. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med., 339: 1341-1348, 1998.
17. Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., Sievers, E. L., Coutre, S., Dahlberg, S., Ellison, R., and Warrell, R. P. J. United states multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol., 19: 3852-3860, 2001.
18. Barbey, J. T., and Soignet, S. L. Arsenic trioxide (ATO): Analysis of QT prolongation on electrocardiogram (ECG). Blood, 96: 319a, 2000.
19. Ohnishi, K., Yoshida, H., Shigeno, K., Nakamura, S., Fujisawa, S., Naito, K., Shinjo, K., Fujita, Y., Matsui, H., Takeshita, A., Sugiyama, S., Satoh, H., Terada, H., and Ohno, R. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann. Intern. Med., 133: 881-885, 2000.
20. Huang, C. H., Chen, W. J., Wu, C. C., Chen, Y. C., and Lee, Y. T. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient. Pacing Clin. Electrophysiol., 22: 965-967, 1999.
21. Unnikrishnan, D., Dutcher, J. P., Varshneya, N., Lucariello, R., Api, M., Garl, S., Wiernik, P. H., and Chiaramida, S. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood, 97: 1514-1516, 2001.
22. Westervelt, P., Brown, R. A., Adkins, D. R., Khoury, H., Curtin, P., Hurd, D., Luger, S. M., Ma, M. K., Ley, T. J., and DiPersio, J. F. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood, 98: 266-271, 2001.
23. Park, W. H., Seol, J. G., Kim, E. S., Hyun, J. M., Jung, C. W., Lee, C. C., Kim, B. K., and Lee, Y. Y. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res., 60: 3065-3071, 2000.
24. Rousselot, P., Labaume, S., Marolleau, J. P., Larghero, J., Noguera, M. H., Brouet, J. C., and Fermand, J. P. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res., 59: 1041-1048, 1999.
25. Munshi, N. C. Arsenic trioxide: An emerging therapy for multiple myeloma. Oncologist, 6 (Suppl. 2): 17-21, 2001.
26. Jing, Y., Dai, J., Chalmers-Redman, R. M., Tatton, W. G., and Waxman, S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood, 94: 2102-2111, 1999.
27. Chen, Y. C., Lin-Shiau, S. Y., and Lin, J. K. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J. Cell Physiol., 177: 324-333, 1998.
28. Wang, T. S., Shu, Y. F., Liu, Y. C., Jan, K. Y., and Huang, H. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology, 121: 229-237, 1997.
29. Dai, J., Weinberg, R. S., Waxman, S., and Jing, Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood, 93: 268-277, 1999.
30. Gregus, Z., and Gyurasics, A. Role of glutathione in the biliary excretion of the arsenical drugs trimelarsan and melarsoprol. Biochem. Pharmacol., 59: 1375-1385, 2000.
31. Liu, J., Chen, H., Miller, D. S., Saavedra, J. E., Keefer, L. K., Johnson, D. R., Klaassen, C. D., and Waalkes, M. P. Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol. Pharmacol., 60: 302-309, 2001.
32. Kala, S. V., Neely, M. W., Kala, G., Prater, C. I., Atwood, D. W., Rice, J. S., and Lieberman, M. W. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J. Biol. Chem., 275: 33404-33408, 2000.
33. May, J. M., Qu, Z., and Li, X. Requirement for GSH in recycling of ascorbic acid in endothelial cells. Biochem. Pharmacol., 62: 873-881, 2001.
34. Meister, A. Glutathione, ascorbate, and cellular protection. Cancer Res., 54: 1969s-1975s, 1994.
35. Bijur, G. N., Ariza, M. E., Hitchcock, C. L., and Williams, M. V. Antimutagenic and promutagenic activity of ascorbic acid during oxidative stress. Environ. Mol. Mutagen., 30, 339-345, 1997.
36. Bachleitner-Hofmann, T., Gisslinger, B., Grumbeck, E., and Gisslinger, H. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br. J. Haematol., 112: 783-786, 2001.
37. Recher, C., Chopin, M., Raffoux, E., Pierron, G., Poupon, J., Sigaux, F., Dombret, H., and Stern, M. H. In vitro and in vivo effectiveness of arsenic trioxide against murine T-Cell prolymphocytic leukemia. Br. J. Haematol., 117: 343-350, 2002.
38. O'Dwyer, P. J., Hamilton, T. C., LaCreta, F. P., Gallo, J. M., Kilpatrick, D., Halbherr, T., Brennan, J., Bookman, M. A., Hoffman, J., Young, R. C., Comis, R. L., and Ozols, R. F. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J. Clin. Oncol., 14: 249-256, 1996.
39. Bailey, H. H., Mulcahy, R. T., Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Tombes, M. B., Wilding, G., Pomplun, M., and Spriggs, D. R. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione. J. Clin. Oncol., 12: 194-205, 1994.
40. Bailey, H. H., Ripple, G., Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Feierabend, C., Mahvi, D., Schink, J., Pomplun, M., Mulcahy, R. T., and Wilding, G. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J. Natl. Cancer Inst. (Bethesda), 89: 1789-1796, 1997.
41. Levine, M., Rumsey, S. C., Daruwala, R., Park, J. B., and Wang, Y. Criteria and recommendations for vitamin C intake. J. Am. Med. Assoc., 281: 1415-1423, 1999.
42. Ohnishi, K., Yoshida, H., Shigeno, K., Nakamura, S., Fujisawa, S., Naito, K., Shinjo, K., Fujita, Y., Matsui, H., Takeshita, A., Sugiyama, S., Satoh, H., Terada, H., and Ohno, R. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann. Intern. Med., 133: 881-885, 2000.
43. Yao, K., Godwin, A. K., Ozols, R. F., Hamilton, T. C., and O'Dwyer, P. J. Variable baseline γ-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res., 53: 3662-3666, 1993.
44. Tehounwou, P. B., Wilson, B., and Ishaque, A. Important considerations in the development of public health advisories for arsenic and arsenic-containing compounds in drinking water. Rev. Environ. Health, 14: 211-229, 1999.